Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7Z2W9
UPID:
RM21_HUMAN
Alternative names:
39S ribosomal protein L21, mitochondrial
Alternative UPACC:
Q7Z2W9; A6NKU0; C9JPR2
Background:
The Large ribosomal subunit protein bL21m, also known as 39S ribosomal protein L21, mitochondrial, plays a crucial role in the synthesis of proteins within the mitochondria. Its involvement in the mitochondrial ribosome highlights its importance in cellular energy production and overall mitochondrial function.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL21m could open doors to potential therapeutic strategies. Its pivotal role in protein synthesis within mitochondria suggests that targeting this protein could lead to novel treatments for diseases related to mitochondrial dysfunction.